ROSWELL, Ga. -- Kimberly-Clark announces that Lynne Kelley, MD, FACS, has been named to the newly created position of vice president, medical director, for the companys $1.2 billion healthcare business. Effective Nov. 5, Kelley assumed responsibilities for the development and delivery of Kimberly-Clark Health Cares clinical strategy and education development, as well as the global coordination of professional and governmental relations.
We are pleased to have Lynne on board to help drive our clinical strategy and look forward to her many contributions, said Kimberly-Clark Health Care president Joanne Bauer. Lynnes impressive credentials and medical expertise will be invaluable to us as we expand our portfolio of medical devices and products to prevent healthcare associated infections.
Kelley is a board-certified general and vascular surgeon who received her medical degree from Dartmouth Medical School and completed her residency in general surgery at Dartmouth Hitchcock Medical Center. During her training, she was awarded an NIH sponsored research grant at Harvard Medical School. Kelley completed a fellowship in vascular surgery at Harvard Medical School at Massachusetts General Hospital and was the recipient of the Marco Polo Fellowship that provided further training in endovascular surgery at the Hospital Henri Mondor, University Paris XII in Créteil, France. Prior to working in the industry, Kelley was an assistant professor of vascular surgery and radiology at Yale University.
I am very excited to be joining the healthcare team at Kimberly-Clark and to be part of a company whose mission is to improve the lives of people worldwide, said Kelley.
Kimberly-Clark is striving to bring its healthcare customers less worry through delivery of clinical solutions to prevent, diagnose and manage healthcare-associated infections and to prevent or reduce complications before, during and after surgery.
Source: Kimberly-Clark Health Care
Â
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.